Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|YLL545||VEGFR2 Inhibitor 35||YLL545 inhibits KDR (VEGFR2), resulting in decreased downstream signaling and potentially leading to decreased angiogenesis and reduced tumor cell proliferation and tumor growth (PMID: 27203384).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||YLL545||Preclinical - Cell line xenograft||Actionable||In a preclinical study, YLL545 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line in culture, and inhibited activation of STAT3 and ERK and decreased tumor growth in TNBC cell line xenograft models (PMID: 27203384).||27203384|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|